Chief Global Strategist Dr. Nelson Teich, Chief Commercial Officer Erin Feeney, and Chief Legal Officer Nicholas Bero Join 4D Path Executive Team
Newton, Massachusetts, February 15, 2022 – 4D Path, a Massachusetts-based company developing a patented computer-aided pan-cancer diagnostic and precision oncology platform, announced it has hired three new executive team members to facilitate the continued advancement of its cloud-based quantitative technology, which is being designed to deliver diagnostic outcomes and enable essential molecular tumor profiling from hematoxylin and eosin (H&E) biopsy/resection histology and cytology images for a full spectrum of cancers. Dr. Nelson Teich, MD, MBA, MSc, Erin Feeney, and Nicholas Bero, J.D. will play critical roles in supporting the continued development of 4D Path’s beachhead product, the Q-Plasia OncoReader Breast, which was awarded FDA Breakthrough Device Designation for its demonstration of potential significant advantages (including improved diagnostic accuracy) over existing approved or cleared alternatives.
Transitioning from his role as a 4D Path advisory board member, world-renowned cancer oncologist, health consultant, and entrepreneur Dr. Teich will now serve as 4D Path’s Chief Global Strategist. Dr. Teich’s expertise in facilitating clinical research and supporting innovative, evidence-based health technologies will support 4D Path’s efforts to bring more readily accessible and affordable care to different countries and their diverse systems, realities, and providers. Prior to joining 4D Path, Dr. Teich served as Brazil’s Minister of Health and as an advisor of the Brazilian Ministry of Health. He was also the owner of Teich & Teich Health Care, a company to support health management. Dr. Teich received his degree in medicine from Rio de Janeiro State University (UERJ) and had his training in Oncology at the Brazilian National Cancer Institute. He has an MBA in health administration from the Institute for Postgraduate Studies and Research in Administration at the Federal University of Rio de Janeiro. He also holds a master's degree in Economic Assessment from the University of York in UK, and has received education in both Management and Entrepreneurship at Harvard Business School.
A dynamic life sciences and biotech executive, Erin Feeney brings extensive experience in early-stage commercialization organizations to her new role as 4D Path’s Chief Commercial Officer. Feeney’s expertise building sales and market access teams across specialty areas, including liquid biopsy, oncology, and women's health, will play a critical role in advancing the commercial strategy and development of 4D Path’s cancer diagnostic and precision oncology platform technology. Feeney most recently served as Vice President of Sales, North America at SOPHiA GENETICS, as well as Vice President of Sequencing Sales at Genuity Science, and Vice President, Global Sales, Clinical Genomics at SeraCare Life Sciences. She received her B.A. in Communications and Political Science at the University of Pittsburgh.
An experienced intellectual property attorney specializing in medical devices, software, and digital health, Nicholas Bero joins 4D Path as Chief Legal Officer. Bero brings a unique perspective that he gained through his broad international legal experience in both top law firms and Fortune 500 companies, which will help guide 4D Path’s continued development of its pan-cancer precision diagnostic and oncology platform. Bero previously served as Principal Counsel for M&A, Strategy, Business Development, Patents at Sanofi, where he acted as a key legal advisor for digital partnering activities, as well as Senior Intellectual Property Counsel at Fresenius Medical Care North America. He received his J.D. from the University of Connecticut School of Law and his B.S. in Electrical and Computer Engineering from the University of Rochester.
“We are pleased to grow our executive team to support the continued development of our revolutionary cancer diagnostic and precision oncology platform, which aims to forge a new path forward in precision oncology by making the routine H&E-stained tissue biopsy not the first step in precision diagnosis, but perhaps the only step,” said Rodrigo Navarro, President and CEO of 4D Path. “Nelson, Erin, and Nicholas will be pivotal in helping to move the 4D Path platform toward implementation and universal accessibility, resulting in the dramatic acceleration of precise, clinically-actionable cancer diagnosis for the betterment of patients worldwide.”
4D Path’s esteemed advisory board is comprised of scientists, clinicians, and management from world-leading research institutions, including Craig A. Bunnell, MD, MPH, MBA – Dana-Farber Cancer Institute, Jennifer Levin Carter, MD, MPH, MBA – JLC Precision Health Strategies, LLC., Barry Fogel MD – Harvard Medical School, Professor Donald Lessard – MIT Sloan School of Management, and Judy C. Lewent – Former Executive Vice President & Chief Financial Officer, Merck & Co.4D Path Boilerplate
Just because you can’t see something, doesn’t mean it’s not there. 4D Path’s mission is to democratize Precision Diagnostics and Oncology by unveiling previously hidden information purely from cellular snapshots of tissue (e.g., histology) or liquid (e.g., cytology) without the use of antibody stains. The company’s cloud-based 4D Q-Plasia OncoReader (QPOR) is a U.S. patented pan-cancer precision diagnostic and oncology platform, which is being designed to extract diagnostic data from routine cytology and histology images. Its beachhead product, the 4D QPOR Breast, has been awarded FDA Breakthrough Device Designation for potentially improving diagnostic accuracy over the current standard of care. This end-to-end solution provides an adjunct tool, which aims to accelerate diagnostic turnaround times, reduce cost, and improve diagnostic accuracy in a single step. In addition, this technology is being designed to identify an overall biologic cancer signature to guide therapeutic management from as early as pre-treatment biopsy/resection specimens. This single test does not require the multiple additive signatures that multi-omics platforms depend upon, with their additional burden of cost, diagnostic delay, and reliance on specialized equipment. This approach toward tumor profiling could lead to the 4D QPOR becoming an extremely efficient and universally accessible platform to better predict and stratify patient response to therapy. The platform can integrate very readily into any existing clinical workflow without altering current practice. Visit www.4dpath.com to learn more.